JOHNSON & JOHNSON
JNJPharma & biotechjnj.com
Latest available resultsSeptember 27, 2026Quarter · 10-Q filed Oct 21, 2026
Next reportJanuary 26, 2027after close · forecast 2.938 $/share
Revenue
$25.40B
▲ +5.9% vs prior year YoY
Net income
$210.00M
▼ -95.9% vs prior year YoY
EPS
0.09$
▼ -95.8% vs prior year YoY
Net margin
0.8%
▼ -20.6 pp vs prior year YoY
Revenue▲ +5.9%
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -95.9%
EPS▼ -95.8%
Financial statements
View 10-Q filed October 21, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B | $25.31B | $25.40B | ▲ +5.9% |
| Gross profit | $15.39B | $14.54B | $16.11B | $16.69B | $16.60B | $15.96B | $17.26B | $17.30B | ▲ +3.7% |
| Operating income | — | — | — | — | — | — | — | — | — |
| Net income | $3.43B | $11.00B | $5.54B | $5.15B | $5.12B | $5.24B | $5.53B | $210.00M | ▼ -95.9% |
| R&D | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 4.54 $ | 2.29 $ | 2.12 $ | — | 2.14 $ | 2.27 $ | 0.09 $ | ▼ -95.8% |
| Margins (% of revenue) | |||||||||
| Gross | 68.3 % | 66.4 % | 67.9 % | 69.6 % | 67.6 % | 66.3 % | 68.2 % | 68.1 % | ▼ -1.4 pt |
| Operating | — | — | — | — | — | — | — | — | — |
| Net | 15.2 % | 50.2 % | 23.3 % | 21.5 % | 20.8 % | 21.8 % | 21.9 % | 0.8 % | ▼ -20.6 pt |
| Balance sheet | |||||||||
| Assets | $180.10B | $193.67B | $193.39B | $192.82B | $199.21B | $200.89B | $201.06B | $197.43B | ▲ +2.4% |
| Liabilities | $108.61B | $115.56B | $114.92B | $113.54B | $117.67B | $119.71B | $116.09B | $115.90B | ▲ +2.1% |
| Equity | $71.49B | $78.11B | $78.47B | $79.28B | $81.54B | $81.19B | $84.97B | $81.53B | ▲ +2.8% |
| Cash | $24.11B | $38.47B | $18.58B | $18.23B | $19.71B | $21.69B | $20.42B | $16.91B | ▼ -7.2% |
| Capital | |||||||||
| Shares outstanding | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | 2.41B | ▼ -0.1% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.